MARKET

AZRX

AZRX

AzurRx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8030
-0.0170
-2.07%
Closed 16:00 05/29 EDT
OPEN
0.8600
PREV CLOSE
0.8200
HIGH
0.8600
LOW
0.7700
VOLUME
276.46K
TURNOVER
--
52 WEEK HIGH
2.290
52 WEEK LOW
0.3709
MARKET CAP
22.05M
P/E (TTM)
-1.2206
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AZRX stock price target is 4.000 with a high estimate of 7.00 and a low estimate of 2.000.

EPS

AZRX News

More
Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX)
Insider Monkey · 2d ago
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
GlobeNewswire · 05/07 13:00
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
GlobeNewswire · 05/05 13:00
AzurRx BioPharma Receives Approximately $721,000 For Its 2019 CIR (French Research Tax Credit)
Received ~$2.52 million in aggregate CIR payments in 2020 CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX)
Benzinga · 05/05 12:12
What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)?
Simply Wall St. · 05/04 11:45
AzurRx up 7% in inclusion of TDN sites in cystic fibrosis study
Seeking Alpha - Article · 04/29 15:08
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites
GlobeNewswire · 04/29 13:00
AzurRx Reports Receives Approval To Conduct Phase 2 OPTION 2 Trial Of MS1819 In Cystic Fibrosis Therapeutics Development Network Sites
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today
Benzinga · 04/29 12:11

Industry

Pharmaceuticals
+1.26%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About AZRX

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
More

Webull offers kinds of AzurRx BioPharma Inc stock information, including NASDAQ:AZRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZRX stock news, and many more online research tools to help you make informed decisions.